The aim of this study was to assess the role of transcatheter aortic valve implantation (TAVI) compared with medical treatment (MT) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis (AS) at increased surgical risk.
Background
Elderly patients with comorbidities are at considerable risk for SAVR.
Methods
Since July 2007, 442 patients with severe AS (age: 81.7 Ϯ 6.0 years, mean logistic European System for Cardiac Operative Risk Evaluation: 22.3 Ϯ 14.6%) underwent treatment allocation to MT (n ϭ 78), SAVR (n ϭ 107), or TAVI (n ϭ 257) on the basis of a comprehensive evaluation protocol as part of a prospective registry.
Results
Baseline clinical characteristics were similar among patients allocated to MT and TAVI, whereas patients allocated to SAVR were younger (p Ͻ 0.001) and had a lower predicted peri-operative risk (p Ͻ 0.001). Unadjusted rates of all-cause mortality at 30 months were lower for SAVR (22.4%) and TAVI (22.6%) compared with MT (61.5%, p Ͻ 0.001). Adjusted hazard ratios for death were 0.51 (95% confidence interval: 0.30 to 0.87) for SAVR compared with MT and 0.38 (95% confidence interval: 0.25 to 0.58) for TAVI compared with MT. Medical treatment (Ͻ0.001), older age (Ͼ80 years, p ϭ 0.01), peripheral vascular disease (Ͻ0.001), and atrial fibrillation (p ϭ 0.04) were significantly associated with all-cause mortality at 30 months in the multivariate analysis. At 1 year, more patients undergoing SAVR (92.3%) or TAVI (93.2%) had New York Heart Association functional class I/II as compared with patients with MT (70.8%, p ϭ 0.003).
Conclusions
Among patients with severe AS with increased surgical risk, SAVR and TAVI improve survival and symptoms compared with MT. Clinical outcomes of TAVI and SAVR seem similar among carefully selected patients with severe symptomatic AS at increased risk. Aortic stenosis (AS) is associated with poor prognosis once symptoms ensue (1, 2) . Surgical aortic valve replacement (SAVR) is the standard of care in the treatment of affected patients by alleviating symptoms and improving survival (3) (4) (5) . Despite favorable results even among high-risk patients, SAVR is not performed in up to one-third of eligible patients, due to advanced age, comorbidities, previous cardiac surgery, depressed left ventricular function, concomi-tant coronary artery disease, and patient refusal (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Transcatheter aortic valve implantation (TAVI) has been introduced as a less-invasive treatment alternative and has been shown to reduce mortality and repeat hospital stays See page 2163 compared with a conservative strategy among patients considered not to be suitable candidates for SAVR (19) . However, it remains to be established how many patients deemed inoperable by cardiac surgeons might indeed qualify for TAVI rather than medical treatment (MT) in routine clinical practice. Moreover, the role of TAVI among patients found to be at increased risk but still considered operable by means of SAVR is unclear. Several registries have shown that TAVI is feasible with the transfemoral, transapical, or subclavian access with favorable results in terms of procedural success, hemodynamic performance, peri-procedural complications, and survival (20 -22) . However, paravalvular aortic regurgitation is more frequent after TAVI than SAVR, and long-term durability of these valves is not yet established. Therefore, selection of the most appropriate therapy among patients with severe AS at increased risk remains difficult today. Since the introduction of TAVI at our institution, all elderly patients with severe AS at increased surgical risk undergo systematic evaluation and subsequent treatment allocation to MT, SAVR, or TAVI by an interdisciplinary team consisting of interventional cardiologists and cardiac surgeons. The aim of the present study was to assess characteristics of patients allocated to a particular treatment strategy (MT, SAVR, TAVI) and to describe clinical outcomes according to treatment selection during mid-term follow-up.
Methods
Patient population. Since July 2007, all elderly patients with symptomatic, severe AS deemed at increased surgical risk were included in this prospective single-center registry. Inclusion criteria were as follows: 1) symptomatic, severe AS with an echocardiographic mean gradient Ͼ40 mm Hg or a calculated aortic valve area Ͻ1 cm 2 ; and 2) age Ն80 years in the presence of a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) Ͼ15%. Patients Ͻ80 years of age were eligible if at least 1 of the following comorbid conditions was present: previous cardiac surgery, chronic obstructive pulmonary disease (forced expiratory volume during 1 s Ͻ1.0), severe pulmonary hypertension (Ն60 mm Hg), porcelain aorta, history of radiation therapy to the mediastinum, or frailty (body mass index Ͻ18 kg/m 2 ). Exclusion criteria consisted of degenerated aortic valve prostheses and severe aortic regurgitation in the absence of AS. The study was approved by the local ethics committee, and all subjects gave written, informed consent. Evaluation and treatment allocation. All patients underwent comprehensive evaluation with a standardized protocol during a short check-up hospital stay, including left and right heart catheterization, aortography, transthoracic and transesophageal echocardiography, and computed tomography (CT) angiography of the chest, abdomen, and pelvis. Clinical risk assessment was performed with the linear and logistic EuroSCORE and Society of Thoracic Surgeons Score (23) . Patients with comorbid conditions including malignancies, prior mediastinal radiation therapy, chronic pulmonary disease, peripheral vascular disease, chronic renal failure, previous cardiac surgery, liver cirrhosis, and bleeding diathesis underwent subspecialty evaluation for complementary risk assessment and treatment recommendation. An interdisciplinary team of interventional cardiologists and cardiac surgeons reviewed the cases and formed a consensus on treatment selection (MT, SAVR, or TAVI) on the basis of individual risk assessment and anatomical and technical considerations as well as patient preferences. Patients were given time to think about the proposed treatment plan and consult with their general practitioner and referring cardiologist. The final treatment allocation was eventually the result of the recommendation as formulated by the Heart Team and patient decision. Crossover from one treatment allocation to another was possible as long as technically feasible.
Medical treatment comprised antithrombotic therapy for treatment of concomitant coronary artery disease or atrial fibrillation, antihypertensive drugs in case of arterial hypertension, statins for treatment of hypercholesterolemia, and diuretics for management of heart failure symptoms, rarely complemented by digoxin. Percutaneous coronary intervention (PCI) was performed in case of coronary artery disease with limiting angina. Isolated balloon aortic valvuloplasty was not performed as part of the MT strategy or as a bridge to SAVR in patients with decompensated heart failure.
Surgical aortic valve replacement was performed through a median sternotomy. Cardiopulmonary bypass was conducted in moderate hypothermia, and myocardial protection was performed with 100 ml of crystalloid cardioplegia (Cardioplexol, SwissCardiotech, Bern, Switzerland). The aorta was cross-clamped and opened at the level of the sinotubular junction. The leaflets were excised, and the aortic annulus was carefully debrided. The annulus was sized with 
Figure 2 Reasons for Treatment Allocation
Reasons for treatment allocation are summarized in columns for each treatment strategy. Anatomic and technical reasons include excessive annulus diameter or inadequate access site diameter not appropriate for a transcatheter approach or porcelain aorta prohibiting cross-clamping of the aorta and hence surgical aortic valve replacement (AVR). Comorbidities with poor prognosis embrace malignancies at an advanced stage, refractory heart failure due to complex valvular heart disease or poor functional status with dementia. Patients with excessive risk for surgical AVR were declined by cardiac surgeons on the basis of peri-operative risk assessment. Patients with low surgical risk were recommended to undergo surgical AVR. Emergency interventions were performed in the setting of severely decompensated heart failure due to aortic stenosis. All patients were treated on the basis of the recommendation formulated by the heart team and the ultimate decision of the patient and family. Values are n (%) or mean Ϯ SD, unless otherwise indicated. *Continuous variables were compared with analysis of variance and categorical variables with Pearson's chi-square test. ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin receptor blockers; BMI ϭ body mass index; CABG ϭ coronary artery bypass grafting; EuroSCORE ϭ European System for Cardiac Operative Risk Evaluation; Lin. ϭ linear; Log. ϭ logarithmic; MI ϭ myocardial infarction; MT ϭ medical treatment; NYHA ϭ New York Heart Association; PAS ϭ pulmonary artery systolic; PCI ϭ percutaneous coronary intervention; SAVR ϭ surgical aortic valve replacement; STS ϭ Society of Thoracic Surgeons; TAVI ϭ transcatheter aortic valve implantation. AVA ϭ aortic valve area; LVEF ϭ left ventricular ejection fraction; PA ϭ pulmonary artery; other abbreviations as in Table 1 . Procedural outcomes. Procedural data including revascularization procedures and concomitant structural heart interventions other than aortic valve replacement are shown in Table 3 . Concomitant coronary revascularization was performed by means of CABG in 43.0% of patients selected for SAVR and by means of PCI in 14.1% of patients allocated to MT and in 14.4% of patients allocated to TAVI. The mean hospital duration was 15.0 Ϯ 20.2 days for patients undergoing SAVR and 10.1 Ϯ 11.6 days for patients undergoing TAVI (p Ͻ 0.001). A permanent pacemaker was implanted in 1.3% of patients allocated to MT, 3.7% of SAVR patients, and 23.3% of TAVI patients (p Ͻ 0.001) (MCRS 29.7% vs. ESV 12.0%; p ϭ 0.001). Surgical re-exploration was necessary in 3.7% of SAVR patients (p ϭ 0.04), whereas TAVI patients underwent covered inguinal stent implantation in 9.7% of cases (p Ͻ 0.001) and inguinal vascular surgery in 3.1% of cases (p ϭ 0.14). The mean number of red blood cell transfusions was 0.06 Ϯ 0.3 packed red blood cells (PRBC) in the MT, 2.5 Ϯ 3.0 PRBC in the SAVR, and 0.5 Ϯ 1.6 PRBC in the TAVI group (p Ͻ 0.001). A RIFLE stage 3 renal failure was present in 1.3% of medical, 1.9% of SAVR, and 3.5% of TAVI patients (p Ͻ 0.001). The mean transvalvular gradient after TAVI was 8.7 Ϯ 4.5 mm Hg, and 28.3% of patients had more than mild (grade Ͼ2ϩ) aortic regurgitation (grade 0/1ϩ: 9.4%, grade 2ϩ: 62.3%, grade 3ϩ: 27.9%, grade 4ϩ: 0.4%). Clinical outcomes. All comparisons referring to clinical outcome are regarded as descriptive. The median follow-up was 379 days (range 46 to 1,163 days) in SAVR patients, 377 days (range 34 to 1,165 days) in TAVI patients, and 643 days (range 204 to 1,290) in patients undergoing MT. None of the patients was lost to follow-up. Event rates with crude and adjusted hazard ratios for all major clinical endpoints at 30 days, 12 months, and 30 months are provided in Tables 4 and 5 . Unadjusted rates of all-cause mortality at 30 months were lower for patients undergoing SAVR (22.4%) and TAVI (22.6%) compared with MT (61.5%, p Ͻ 0.001) (Fig. 3A) . The adjusted hazard ratio for death was 0.51 (95% CI: 0.30 to 0.87) for SAVR compared with MT and 0.38 (95% CI: 0.25 to 0.58) for TAVI compared with MT. Major stroke occurred with similar frequency in all 3 groups with an adjusted hazard ratio of 1.12 (95% CI: 0.28 to 4.98) for SAVR compared with MT and 0.91 (95% CI: 0.25 to 3.35) for TAVI compared with MT. Event rates for major adverse cardiac events and MACCE were lower for both SAVR (24.3%) and TAVI (25.7%) compared with MT (64.1%) with an adjusted hazard ratio of 0.51 (95% CI: 0.31 to 0.87) for SAVR compared with MT and 0.39 (95% CI: 0.26 to 0.60) for TAVI compared with MT (Fig. 3B) . A stratified analysis of aortic valve replacement therapy (surgical or transcatheter) compared with MT for all-cause mortality at 30 months revealed consistent results across all studied subgroups without evidence of a significant interaction (Fig. 4A ). Medical treatment, older age (Ͼ80 years), peripheral vascular disease, and atrial fibrillation at baseline were associated with all-cause mortality at 30 months in the multivariable regression analysis (Table 6) . A stratified comparison between TAVI and SAVR identified no significant differences between the 2 treatment strategies (Fig. 4B) . Symptom status at various follow-up times is shown in Figure 5 
2155
JACC Vol. 58, No. 21, 2011 Wenaweser et al. November 15, 2011:2151-62 Severe AS and Treatment
Discussion
This observational single-center study of treatment selection and mid-term clinical outcomes among patients with severe AS deemed at increased surgical risk shows the following main findings: 1) patients allocated to MT and TAVI had similar baseline clinical characteristics, whereas patients undergoing SAVR were younger and had lower perioperative risk scores but underwent coronary revascularization more often; 2) MT of high-risk patients with severe AS was associated with a dismal prognosis; 3) aortic valve replacement therapy by means of SAVR or TAVI resulted in improved survival and symptom status compared with MT; and 4) all-cause mortality and MACCE did not differ among patients allocated to SAVR, compared with TAVI. The patient population of the present study comprised elderly (mostly octogenarians) patients with frequent comorbidities considered at increased risk for SAVR. Baseline clinical characteristics of patients allocated to MT or TAVI were much alike, whereas those undergoing SAVR were somewhat younger and had less comorbidity, suggesting that patients allocated to TAVI were mainly recruited from the pool of patients formerly treated conservatively. Irrespective of the treatment allocation to either SAVR or TAVI, the long-term survival of patients undergoing intervention for severe AS was improved, as compared with patients allocated to MT in general as well as across most patient subgroups (Fig. 4A) . The benefit in terms of survival with both SAVR and TAVI was associated with a sustained improvement in symptom status (Fig. 5) .
Several previous studies have highlighted the poor outcome of patients with severe AS treated conservatively (2) (3) (4) (5) . Recently, TAVI has been shown to lower mortality from 51% to 31% and repeat-hospital-stay rate from 44% to 22%, compared with MT, in a randomized trial of elderly patients with severe AS considered not to be suitable candidates for SAVR (19) . The present study confirms the dismal prognosis of patients treated conservatively and extends the findings to a contemporary patient population with consideration of all currently available treatment options. Furthermore, it represents a cohort of consecutive and unselected patients referred to a tertiary care center with extended follow-up to 30 months. Similar to the results of the PARTNER B (Placement of AoRtic TraNscathetER Valve Trial) (19) , the observed treatment effect in terms of mortality was large (Ͼ50% relative risk reduction) for both crude and adjusted outcome variables, and the risk of peri-procedural complications associated with TAVI and SAVR did not exceed short-term mortality among patients allocated to MT. Moreover, surgical and transcatheter aortic valve replacement were associated with marked and sustained improvement in quality of life as compared with MT. Of note, all patients had been referred for evaluation of a possible intervention, and the reason for a conservative strategy was patient refusal of any procedure despite recommendation of an invasive treatment strategy in the majority of cases. This
Predictors of All-Cause Mortality at 30 Months observation is further substantiated by the similarity of patient characteristics and risk scores among patients allocated to MT and TAVI and suggests that TAVI addresses an unmet clinical need.
Only limited evidence exists for the comparison of TAVI with SAVR to date. In a 2-center study of 1,122 patients comparing TAVI (n ϭ 114) with SAVR (n ϭ 1008), patients undergoing TAVI were older and had heart failure more frequently, a higher logistic EuroSCORE, and more comorbidities. Crude mortality at 30 days was 9.6% for TAVI and 2.3% for SAVR (odds ratio: 4.57, 95% CI: 2.2 to 9.7). The adjusted odds ratio of 30-day mortality ranged from as low as 0.6 to as high as 7.6, depending on the method used precluding any definitive conclusions as to the relative safety of the 2 procedures (24). A propensity-score matched analysis of 100 paired patients undergoing either transapical TAVI or SAVR reported similar survival rates at 1 year (TAVI: 73 Ϯ 4%, SAVR: 69 Ϯ 5%, p ϭ 0.55) (25) . Descoutures et al. (26) reported clinical outcome among 66 consecutive patients with severe AS after allocation to MT, SAVR, and TAVI. At 6-month follow-up, mortality among discharged patients amounted to 29% among MT patients, whereas all patients treated by TAVI or SAVR had survived. In the present study, we observed differences in the rate and type of peri-procedural complications between SAVR and TAVI. Patients undergoing TAVI more frequently suffered from atrioventricular conduction disturbances requiring permanent pacemaker implantation and had a higher rate of aortic regurgitation, access site complications, and RIFLE stage 3 renal failure, whereas patients undergoing SAVR more frequently required re-exploration and had more blood transfusions and longer hospital stays. However, mortality, major stroke, and MACCE occurred with similar frequency among patients allocated to TAVI and SAVR for both crude and adjusted outcomes during long-term follow-up. The findings for the comparison of TAVI with SAVR in terms of mortality were consistent across major subgroups, although the results have to be interpreted with caution in view of the limited sample size (Fig. 4B) .
The first randomized comparison of TAVI and SAVR among high-risk patients with severe AS revealed similar outcomes in terms of mortality at 1 year (27) . The present study not only corroborates these findings in a nonrandomized case series but also extends the observation to a follow-up duration of 30 months in a large, consecutive, and therefore unselected patient population as encountered in routine clinical practice. Nevertheless, the higher rate of paravalvular aortic regurgitation after TAVI and the uncertain long-term durability of percutaneously implanted valve prostheses require further scrutiny. Study limitations. First, enrollment of patients into this registry was based on referral from a primary or secondary care facility with the primary intention of an active treatment for severe AS, hence forestalling a certain selection of patients potentially qualifying for an intervention. Second, the data were acquired in a single tertiary care center, and results might not be generalizable to institutions with different referral patterns and collaborations between interventional cardiologists and cardiac surgeons. Third, this was not a randomized comparison between MT, SAVR, and TAVI, and therefore the results might be regarded as descriptive. However, treatment effects in favor of SAVR and TAVI as compared with MT were large, and findings were robust after adjustment for differences in baseline clinical characteristics. Moreover, the study provides outcome data for all treated patients and therefore represents treatment decision and outcomes of unselected patients as encountered in routine clinical practice. Fourth, revascularization was more commonly performed among patients undergoing SAVR than among those allocated to TAVI. It is well known that SAVR combined with revascularization is associated with an increased risk as compared with 
